Latest news with #KIT
Malaysian Reserve
7 days ago
- Entertainment
- Malaysian Reserve
Esports World Cup 2025 Press Conference Kicks Off in Riyadh
Seven-week tournament features 2,000 players, 25 titles, and the top 200 Clubs competing in the world's largest cross-game esports competition, championed by global icons and EWC Ambassadors Cristiano Ronaldo and Magnus Carlsen PRESS KIT RIYADH, Saudi Arabia, July 10, 2025 /PRNewswire/ — The Esports World Cup Foundation (EWCF) has launched the opening press conference for the 2025 Esports World Cup (EWC) in Riyadh, Saudi Arabia, officially marking the start of the world's largest esports and gaming festival. Running until August 24, the event features more than 2,000 elite players, 25 tournaments across 24 leading titles, and a record-breaking prize pool of over $70 million, cementing its status as the biggest and most significant esports event ever staged. EWC 2025 brings together the world's top 200 Clubs to compete in a first-of-its-kind cross-title format. At the heart of the competition is the Club Championship, where teams accumulate points across multiple games to become the EWC Club Champion, claim a $7 million grand prize and hoist the coveted EWC Club Championship trophy. The $70+ million prize pool also includes $38+ million for individual Game Championships, $5 million in global qualifier rewards, and $450,000 in MVP bonuses. Speaking at the opening press conference, HRH Prince Faisal bin Bandar bin Sultan, Chairman, Saudi Esports Federation, said: 'Guided by the ambitious vision and leadership of His Royal Highness Prince Mohammed bin Salman bin Abdulaziz AlSaud, Crown Prince and Prime Minister of Saudi Arabia, the Kingdom is cementing its position as a global leader in gaming and esports. The Esports World Cup is a clear reflection of that progress. We are immensely proud to welcome back the world in Riyadh for the Esports World Cup. This event stands as a global milestone for esports by showcasing the scale, ambition, and future of competitive gaming. It is a moment that will shape the direction of the industry for years to come.' He continued: 'Hosting this event reflects our deep commitment to building a world-class, sustainable esports ecosystem. It demonstrates the Kingdom's belief in the power of gaming to connect, inspire, and create meaningful opportunities for future generations. It also supports our broader ambition to diversify the economy and position the Kingdom as a global hub for sports, gaming, and entertainment in line with Vision 2030 and the National Gaming and Esports Strategy. Esports is no longer niche. It is a global sport, a cultural movement, and the Esports World Cup is its most powerful and unifying stage. We are honoured to lead this transformation and shape the future of the industry from here in Saudi Arabia.' 'EWC 2025 is about bringing the gaming world together – iconic games, elite players, and millions of fans around a shared celebration,' said Ralf Reichert, CEO of the Esports World Cup Foundation. 'Through new ways of global broadcasts, original shows, and documentary storytelling, we're opening doors, creating opportunities, and sharing esports in new and exciting ways. With record-breaking competition, this summer is special—not just for gamers, but for everyone who joins us.' Faisal bin Homran, Chief Product Officer, Esports World Cup Foundation, added: 'The Esports World Cup is redefining what's possible in esports. It brings together the world's top teams to compete in the most iconic and advanced arenas, delivering a level of excitement that is unmatched across the industry. Through EWC, the world has witnessed inspiring stories of triumph, heartbreak and glory, for players, teams and communities across the world.' He continued: 'The event is also a powerful platform for leading publishers, brands and creators to connect with global audiences and shape the future of esports. As we look ahead to EWC 2025, we invite the world to be part of what comes next. Together, we are setting new standards, creating new opportunities and driving the industry forward.' Tomorrow, 10 July, the Esports World Cup kicks off with a star-studded Opening Ceremony featuring Post Malone, DINO of SEVENTEEN, and Alesso launching a summer of elite competition and world-class entertainment in Riyadh. About The Esports World Cup: The Esports World Cup (EWC) is a premier annual sporting event and global celebration of competitive excellence and esports fandom. The competition features a unique cross-game format that pits the world's top esports Clubs against one another for the largest prize pool in esports history. Returning to Riyadh, Saudi Arabia, in the summer of 2025, the EWC will bring gaming and esports communities together again to crown the next Esports World Cup Club Champion. Photo:
Business Times
23-06-2025
- Business
- Business Times
Stocks to watch: OCBC, Fu Yu, Keppel Infrastructure Trust
[SINGAPORE] The following companies saw new developments that may affect trading of their securities on Monday (Jun 23): OCBC: The lender has committed more than RM11 billion (S$3.3 billion) in financing to support businesses in the Johor-Singapore Special Economic Zone (JS-SEZ) since 2024, the bank said on Sunday. By end-2025, it expects to provide at least RM3 billion more in financing for real estate, oil and gas, manufacturing and data centres, which will further catalyse economic activities and cross border investments in Johor and the JS-SEZ. The counter finished on Friday 0.6 per cent or S$0.09 lower at S$15.90, before the announcement. Fu Yu: Four proposed directors have been assessed by an independent party who made no findings against their suitability for the role, the components manufacturer said on Friday. This follows the resignation of three of Fu Yu's directors on Jun 11, which left the group with only one director on its board. The group added that the proposed candidates are not involved in matters relating to its unit, Fu Yu Supply Chain Solutions, which is under investigation. Fu Yu ended on Friday at S$0.09, down 4.3 per cent. Keppel infrastructure Trust (KIT): The board of KIT, in its capacity as trustee-manager, has obtained S$25 million in bank facilities, it said on Friday. It will be required to pay all outstanding loans under the facility agreement immediately should it cease to be KIT's trustee-manager, if its ability to perform payment or material obligations under the agreement are restricted due to matters relating to it or if the replacement or substitute trustee-manager is not appointed according to the KIT trust deed's terms or applicable law. Units of KIT ended on Friday 1.3 per cent or S$0.005 lower at S$0.39, before the announcement.
Yahoo
12-06-2025
- Business
- Yahoo
Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025
Seven months after the completion of dosing: 41% of patients (150 mg Q4W) continue to experience complete response (UAS7=0) 48% of patients (150 mg Q4W) report that CSU no longer impacts their quality of life (DLQI=0/1) KIT related tolerability events demonstrated to be reversible Enrollment to Phase 3 CSU trials ongoing Company to host webcast today at 6:00 pm ET HAMPTON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating profound, sustained complete response and improved quality of life at 76 weeks, 7 months after the completion of dosing with barzolvolimab in chronic spontaneous urticaria (CSU), an immune-related condition driven by mast cell activation. Barzolvolimab specifically targets mast cells by binding the receptor tyrosine kinase KIT with high specificity and potently inhibiting its activity, which is required for mast cell function and survival. The data are being presented in a late breaking oral presentation (#100227) at the EAACI Congress 2025. The Company previously announced that this Phase 2 study of barzolvolimab in patients with moderate to severe CSU refractory to antihistamines, including patients with biologic-refractory disease, met its primary endpoint—a significant improvement in UAS7 compared to placebo at 12 weeks—across all dose groups tested. Barzolvolimab also demonstrated rapid, profound complete response rates (UAS7=0; no itch/no hives) in up to 51% of patients at 12 weeks, which continued to deepen over 52 weeks of active therapy to up to 71% of patients. Seven months after completion of dosing, patients continue to experience profound clinical benefit, with up to 41% of patients reporting a complete response at 76 weeks and 48% of patients reporting that their disease no longer impacts their quality of life. Barzolvolimab demonstrated a well tolerated safety profile throughout the study. 'In this large Phase 2 study, patients on barzolvolimab experienced rapid, profound, durable complete response which correlated with meaningful improvements in quality of life—the goal of treatment for patients and physicians,' said Martin Metz, M.D., Professor, Department of Dermatology and Allergy, Head of Translational Research and Deputy Head of Clinical Trials at Charité – Universitätsmedizin in Berlin and the lead investigator of the study. 'By addressing the root driver of chronic spontaneous urticaria, the mast cell, barzolvolimab provided meaningful clinical benefit to more than 90% of the patients on study, including patients with severe disease refractory to omalizumab, and demonstrated a level of sustained complete response after the completion of active therapy that is unprecedented in CSU. Importantly, across this large, 76 week Phase 2 trial, barzolvolimab also presented a favorable safety profile, further supporting barzolvolimab's significant potential to become a transformative treatment option for patients suffering from this often very severe and debilitating disease.' Data highlights at 76 weeks (7 months/28 weeks after completion of barzolvolimab treatment) Rapid, profound improvements in UAS7 (weekly urticaria activity score) were reported as early as one week after dosing. Barzolvolimab achieved the primary efficacy endpoint, a statistically significant mean change from baseline to Week 12 in UAS7 (weekly urticaria activity score) compared to placebo, at all dose levels. These improvements were sustained or deepened at Week 52 and continued to Week 76. UAS7 mean change from baseline at Week 76 was -20.42 for patients treated with 150 mg Q4W and -21.10 for patients treated with 300 mg Q8W. 41% of patients treated with barzolvolimab 150 mg Q4W and 35% of patients treated with 300 mg Q8W had a complete response (no itch/hives; UAS7=0) at Week 76. 56% of patients treated with barzolvolimab 150 mg Q4W and 47% of patients treated with 300 mg Q8W had well controlled disease (UAS7≤6) at Week 76. 48% of patients treated with barzolvolimab 150 mg Q4W and 40% of patients treated with 300 mg Q8W reported that CSU had no impact on their quality of life at 76 weeks as measured by the Dermatology Life Quality Index (DLQI). Current clinical guidelines recommend complete response (UAS7=0) as the goal of treatment1 and achieving complete response is directly correlated to the greatest improvements in quality of life for patients2. These robust responses and improvements in quality of life were observed regardless of prior omalizumab experience. Barzolvolimab was well tolerated with a favorable safety profile through 76 weeks. The most common adverse events were grade 1 (mild), mechanism related (KIT) and reversible. No new safety signals were identified during the follow-up period. As previously disclosed, neutropenia events resolved rapidly and while still receiving barzolvolimab treatment and there was no association between neutropenia and infections. As expected, neutrophil counts returned to baseline following the completion of barzolvolimab treatment and the mild hair color changes and skin hypopigmentation observed on study were demonstrated to be reversible following discontinuation of treatment. 'At every analysis across multiple endpoints in this Phase 2 study, barzolvolimab has demonstrated best in disease data, suggesting barzolvolimab holds great promise as a transformational treatment for patients suffering from CSU— a disease of misery that often impacts all aspects of patients' lives,' said Diane C. Young, M.D., Senior Vice President and Chief Medical Officer of Celldex. 'On behalf of Celldex, I want to thank the patients and physicians who participated in this study. We remain diligently focused on executing across our clinical trials to bring this potential important new medicine to patients.' Results presented at the EAACI Congress 2025 are available on the "Publications' page of the "Science" section of the Celldex website. 1Zuberbier T, et al. Allergy, 2022; 2Kolkhir P, et al. JACI, 2023 Webcast The Company will host a conference call/webcast today to discuss the results at 6:00 pm ET. To access the live and archived webcast, please visit the Events section on the Investor Relations page of Celldex's website. Parties interested in participating via telephone may register here to receive the dial-in numbers and unique PIN to seamlessly access the call. Otherwise please access the listen-only webcast link. The archived webcast will be available for a limited time on the Company's website. About BarzolvolimabBarzolvolimab is a humanized monoclonal antibody that binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. KIT is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells. In certain inflammatory diseases, such as chronic urticaria, mast cell activation plays a central role in the onset and progression of the disease. Barzolvolimab is currently being studied in chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), prurigo nodularis (PN), eosinophilic esophagitis (EOE) and atopic dermatitis (AD), with additional indications planned for the future. About the Phase 2 CSU StudyThe randomized, double-blind, placebo-controlled, parallel group Phase 2 study evaluated the efficacy and safety profile of multiple dose regimens of barzolvolimab in patients with CSU who remain symptomatic despite antihistamine therapy, to determine the optimal dosing strategy. 208 patients were randomly assigned on a 1:1:1:1 ratio to receive subcutaneous injections of barzolvolimab at 75 mg every 4 weeks, 150 mg every 4 weeks, 300 mg every 8 weeks or placebo during a 16-week placebo-controlled treatment period. After 16 weeks, patients then entered a 36-week active treatment period, in which patients receiving placebo or the 75 mg dose were randomized to receive barzolvolimab 150 mg every 4 weeks or 300 mg every 8 weeks; patients already randomized to the 150 mg and 300 mg treatment arms remained on the same regimen as during the placebo-controlled treatment period. After 52 weeks, patients enter a follow-up period for an additional 24 weeks. Barzolvolimab achieved the primary efficacy endpoint of the study—a statistically significant mean change from baseline to week 12 in UAS7 (weekly urticaria activity score) compared to placebo at all dose levels. For additional information on this trial (NCT05368285), please visit About the Phase 3 ProgramCelldex is currently conducting a global Phase 3 Program for barzolvolimab in CSU, consisting of two Phase 3 trials (EMBARQ-CSU1; NCT06445023 and EMBARQ-CSU2; NCT06455202) designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic despite H1 antihistamine treatment. The studies also include patients who remain symptomatic after treatment with biologics. Enrollment is underway. About Chronic Spontaneous Urticaria (CSU)CSU is characterized by the occurrence of hives or wheals for 6 weeks or longer without identifiable specific triggers or causes. The activation of the mast cells in the skin (release of histamines, leukotrienes, chemokines) results in episodes of itchy hives, swelling and inflammation of the skin that can go on for years or even decades. Current therapies provide symptomatic relief only in some patients. About Celldex Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune Forward Looking StatementThis release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of Company drug candidates, including barzolvolimab (also referred to as CDX-0159), in current or future indications; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the availability, cost, delivery and quality of clinical materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; our ability to continue to obtain capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; and other factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise. Company ContactSarah CavanaughSenior Vice President, Corporate Affairs & Administration(508) 864-8337scavanaugh@ Patrick TillMeru Advisors(484) 788-8560ptill@
Yahoo
12-06-2025
- Business
- Yahoo
Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025
Seven months after the completion of dosing: 41% of patients (150 mg Q4W) continue to experience complete response (UAS7=0) 48% of patients (150 mg Q4W) report that CSU no longer impacts their quality of life (DLQI=0/1) KIT related tolerability events demonstrated to be reversible Enrollment to Phase 3 CSU trials ongoing Company to host webcast today at 6:00 pm ET HAMPTON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating profound, sustained complete response and improved quality of life at 76 weeks, 7 months after the completion of dosing with barzolvolimab in chronic spontaneous urticaria (CSU), an immune-related condition driven by mast cell activation. Barzolvolimab specifically targets mast cells by binding the receptor tyrosine kinase KIT with high specificity and potently inhibiting its activity, which is required for mast cell function and survival. The data are being presented in a late breaking oral presentation (#100227) at the EAACI Congress 2025. The Company previously announced that this Phase 2 study of barzolvolimab in patients with moderate to severe CSU refractory to antihistamines, including patients with biologic-refractory disease, met its primary endpoint—a significant improvement in UAS7 compared to placebo at 12 weeks—across all dose groups tested. Barzolvolimab also demonstrated rapid, profound complete response rates (UAS7=0; no itch/no hives) in up to 51% of patients at 12 weeks, which continued to deepen over 52 weeks of active therapy to up to 71% of patients. Seven months after completion of dosing, patients continue to experience profound clinical benefit, with up to 41% of patients reporting a complete response at 76 weeks and 48% of patients reporting that their disease no longer impacts their quality of life. Barzolvolimab demonstrated a well tolerated safety profile throughout the study. 'In this large Phase 2 study, patients on barzolvolimab experienced rapid, profound, durable complete response which correlated with meaningful improvements in quality of life—the goal of treatment for patients and physicians,' said Martin Metz, M.D., Professor, Department of Dermatology and Allergy, Head of Translational Research and Deputy Head of Clinical Trials at Charité – Universitätsmedizin in Berlin and the lead investigator of the study. 'By addressing the root driver of chronic spontaneous urticaria, the mast cell, barzolvolimab provided meaningful clinical benefit to more than 90% of the patients on study, including patients with severe disease refractory to omalizumab, and demonstrated a level of sustained complete response after the completion of active therapy that is unprecedented in CSU. Importantly, across this large, 76 week Phase 2 trial, barzolvolimab also presented a favorable safety profile, further supporting barzolvolimab's significant potential to become a transformative treatment option for patients suffering from this often very severe and debilitating disease.' Data highlights at 76 weeks (7 months/28 weeks after completion of barzolvolimab treatment) Rapid, profound improvements in UAS7 (weekly urticaria activity score) were reported as early as one week after dosing. Barzolvolimab achieved the primary efficacy endpoint, a statistically significant mean change from baseline to Week 12 in UAS7 (weekly urticaria activity score) compared to placebo, at all dose levels. These improvements were sustained or deepened at Week 52 and continued to Week 76. UAS7 mean change from baseline at Week 76 was -20.42 for patients treated with 150 mg Q4W and -21.10 for patients treated with 300 mg Q8W. 41% of patients treated with barzolvolimab 150 mg Q4W and 35% of patients treated with 300 mg Q8W had a complete response (no itch/hives; UAS7=0) at Week 76. 56% of patients treated with barzolvolimab 150 mg Q4W and 47% of patients treated with 300 mg Q8W had well controlled disease (UAS7≤6) at Week 76. 48% of patients treated with barzolvolimab 150 mg Q4W and 40% of patients treated with 300 mg Q8W reported that CSU had no impact on their quality of life at 76 weeks as measured by the Dermatology Life Quality Index (DLQI). Current clinical guidelines recommend complete response (UAS7=0) as the goal of treatment1 and achieving complete response is directly correlated to the greatest improvements in quality of life for patients2. These robust responses and improvements in quality of life were observed regardless of prior omalizumab experience. Barzolvolimab was well tolerated with a favorable safety profile through 76 weeks. The most common adverse events were grade 1 (mild), mechanism related (KIT) and reversible. No new safety signals were identified during the follow-up period. As previously disclosed, neutropenia events resolved rapidly and while still receiving barzolvolimab treatment and there was no association between neutropenia and infections. As expected, neutrophil counts returned to baseline following the completion of barzolvolimab treatment and the mild hair color changes and skin hypopigmentation observed on study were demonstrated to be reversible following discontinuation of treatment. 'At every analysis across multiple endpoints in this Phase 2 study, barzolvolimab has demonstrated best in disease data, suggesting barzolvolimab holds great promise as a transformational treatment for patients suffering from CSU— a disease of misery that often impacts all aspects of patients' lives,' said Diane C. Young, M.D., Senior Vice President and Chief Medical Officer of Celldex. 'On behalf of Celldex, I want to thank the patients and physicians who participated in this study. We remain diligently focused on executing across our clinical trials to bring this potential important new medicine to patients.' Results presented at the EAACI Congress 2025 are available on the "Publications' page of the "Science" section of the Celldex website. 1Zuberbier T, et al. Allergy, 2022; 2Kolkhir P, et al. JACI, 2023 Webcast The Company will host a conference call/webcast today to discuss the results at 6:00 pm ET. To access the live and archived webcast, please visit the Events section on the Investor Relations page of Celldex's website. Parties interested in participating via telephone may register here to receive the dial-in numbers and unique PIN to seamlessly access the call. Otherwise please access the listen-only webcast link. The archived webcast will be available for a limited time on the Company's website. About BarzolvolimabBarzolvolimab is a humanized monoclonal antibody that binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. KIT is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells. In certain inflammatory diseases, such as chronic urticaria, mast cell activation plays a central role in the onset and progression of the disease. Barzolvolimab is currently being studied in chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), prurigo nodularis (PN), eosinophilic esophagitis (EOE) and atopic dermatitis (AD), with additional indications planned for the future. About the Phase 2 CSU StudyThe randomized, double-blind, placebo-controlled, parallel group Phase 2 study evaluated the efficacy and safety profile of multiple dose regimens of barzolvolimab in patients with CSU who remain symptomatic despite antihistamine therapy, to determine the optimal dosing strategy. 208 patients were randomly assigned on a 1:1:1:1 ratio to receive subcutaneous injections of barzolvolimab at 75 mg every 4 weeks, 150 mg every 4 weeks, 300 mg every 8 weeks or placebo during a 16-week placebo-controlled treatment period. After 16 weeks, patients then entered a 36-week active treatment period, in which patients receiving placebo or the 75 mg dose were randomized to receive barzolvolimab 150 mg every 4 weeks or 300 mg every 8 weeks; patients already randomized to the 150 mg and 300 mg treatment arms remained on the same regimen as during the placebo-controlled treatment period. After 52 weeks, patients enter a follow-up period for an additional 24 weeks. Barzolvolimab achieved the primary efficacy endpoint of the study—a statistically significant mean change from baseline to week 12 in UAS7 (weekly urticaria activity score) compared to placebo at all dose levels. For additional information on this trial (NCT05368285), please visit About the Phase 3 ProgramCelldex is currently conducting a global Phase 3 Program for barzolvolimab in CSU, consisting of two Phase 3 trials (EMBARQ-CSU1; NCT06445023 and EMBARQ-CSU2; NCT06455202) designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic despite H1 antihistamine treatment. The studies also include patients who remain symptomatic after treatment with biologics. Enrollment is underway. About Chronic Spontaneous Urticaria (CSU)CSU is characterized by the occurrence of hives or wheals for 6 weeks or longer without identifiable specific triggers or causes. The activation of the mast cells in the skin (release of histamines, leukotrienes, chemokines) results in episodes of itchy hives, swelling and inflammation of the skin that can go on for years or even decades. Current therapies provide symptomatic relief only in some patients. About Celldex Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune Forward Looking StatementThis release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of Company drug candidates, including barzolvolimab (also referred to as CDX-0159), in current or future indications; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the availability, cost, delivery and quality of clinical materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; our ability to continue to obtain capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; and other factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise. Company ContactSarah CavanaughSenior Vice President, Corporate Affairs & Administration(508) 864-8337scavanaugh@ Patrick TillMeru Advisors(484) 788-8560ptill@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Times
11-06-2025
- Business
- Business Times
Stocks to watch: Keppel Infrastructure Trust, Raffles Medical, Amara, Koh Brothers Eco Engineering, SIA
[SINGAPORE] The following companies saw new developments that may affect trading of their securities on Wednesday (Jun 11): Keppel Infrastructure Trust (KIT) : Its manager is divesting a 24.6 per cent stake in Australian bus service business Ventura Motors for A$130 million (S$109 million). As part of the trust's value creation strategy, the sale will bolster its financial strength and agility while enhancing its ability to capture further opportunities through strategic capital recycling, said Kevin Neo, chief executive of the manager, on Tuesday. Units of KIT closed flat at S$0.395 on Tuesday, before the announcement. Raffles Medical Group : The group has inked a strategic cooperation agreement with First Affiliated Hospital, a hospital in Chongqing, China, to deepen medical partnerships between the two. Under the partnership, a new healthcare collaboration ecosystem will be set up, where the two parties will participate in reciprocal visits and exchanges for personnel and explore new models of cooperation such as on artificial intelligence applications. A new medical consortium will facilitate the flow of medical resources and top expert teams from both hospitals will convene for academic exchanges and consultations, the group said on Tuesday. Shares of Raffles Medical closed at S$0.975 on Tuesday, down 1 per cent or S$0.01, before the announcement. Amara : The hotel and property group will be delisted from the Singapore Exchange as the privatisation offer for it closed with valid acceptances representing 97.74 per cent of total shares. As at the offer's close at 5.30 pm on Tuesday, the total number of shares owned, controlled or agreed to be acquired by the offeror DRC Investments, together with valid acceptances of the offer, was 562 million shares. DRC, a consortium led by property developer Hwa Hong, will compulsorily acquire all remaining shares of Amara it does not own at the price of S$0.895 apiece and make the group its wholly owned subsidiary. Shares of Amara were suspended on Tuesday. Koh Brothers Eco Engineering ; Singapore Airlines : A joint venture between Japanese firm Penta-Ocean Construction and a subsidiary of the construction and engineering company bagged a S$999 million contract for the construction of intra-terminal tunnels at Changi Airport's upcoming Terminal 5 (T5). The intra-terminal tunnels will serve as underground connections within T5, support the transfer of passengers and baggage across the terminal's concourses while facilitating the routing of common utilities, said Changi Airport Group on Tuesday. When T5 opens in the mid-2030s, it will consolidate the operations of Singapore Airlines and Scoot, which are now spread across three terminals. Shares of Koh Brothers Eco Engineering ended on Tuesday 5.7 per cent or S$0.003 lower at S$0.05, before the announcement; SIA shares closed on Tuesday 0.6 per cent or S$0.04 higher at S$7.10 before the announcement.
